Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients

NCT00206154 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00206154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00206154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2005
Completion date
December 31, 2006
Enrollment
1,500 (estimated)
Sites
212

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease